No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Honz Pharmaceutical (300086.SZ): Cefoperazone ester tablets pass the consistency evaluation of generic drugs.
Gelonghui, February 27th丨Honz Pharmaceutical (300086.SZ) announced that the company recently received a Supplementary Application Approval Notice for Cefoperazone Ester Tablets issued by the National Medical Products Administration. The Cefoperazone Ester Tablets have passed the consistency evaluation of quality and efficacy for generic drugs. Cefoperazone Ester is an orally administered broad-spectrum third-generation cephalosporin, which is hydrolyzed by nonspecific esterases in the body to Cefoperazone to exert its antibacterial effects. Its mechanism of action is achieved by inhibiting the biosynthesis of microbial cell walls, resulting in a bactericidal effect, effective against both Gram-positive and Gram-negative bacteria. The clinical demand is stable, and it is used to treat infections caused by sensitive bacteria, including: 1. Upper respiratory.
Honz Pharmaceutical (300086.SZ): The financial director has changed to Li Jing.
On February 24, Gelo Exchange reported that Honz Pharmaceutical (300086.SZ) announced that on February 24, 2025, the Sixth Board of Directors held its seventeenth meeting to review and approve the "Proposal for Changing the Company's Chief Financial Officer." Due to internal adjustments, the Board of Directors agreed that Mr. Han Dingfu would no longer serve as the Chief Financial Officer of the company (the original term was from July 24, 2024, to December 14, 2025) but would still hold the position of Director of Internal Control and Compliance. As of the announcement date, Mr. Han Dingfu did not directly or indirectly hold.
Kangzhi Pharmaceutical: 2024 Annual Results Forecast
Honz Pharmaceutical (300086.SZ): Wholly-owned subsidiary Shenyang Honz adjusts land use and pays additional land transfer fees, and a small portion of the land is acquired by the government for compensation.
On December 25, Gelonghui reported that Honz Pharmaceutical (300086.SZ) announced that, in response to the social and economic development plan of Shenyang Economic and Technological Development Zone and the relevant planning adjustments from Tiexi District, Shenyang, and in accordance with the "Shenyang Urban Renewal Management Measures," in order to revitalize the company's idle Assets, after consultations with the Shenyang Natural Resources Bureau regarding land use adjustments, both parties intend to agree: to adjust 36,104.22 square meters of land designated for industrial use out of a total land area of 40,462.67 square meters registered to Shenyang Honz Pharmaceutical to business use (compatible with commercial use), and this change in land usage requires the payment of land fees.
Honz Pharmaceutical's (SZSE:300086) Growing Losses Don't Faze Investors as the Stock Hikes 27% This Past Week
Honz Pharmaceutical Co., Ltd.'s (SZSE:300086) Business Is Yet to Catch Up With Its Share Price